Filing Details
- Accession Number:
- 0001493152-16-015281
- Form Type:
- 4/A
- Zero Holdings:
- No
- Publication Time:
- 2016-11-18 17:12:19
- Reporting Period:
- 2016-04-19
- Filing Date:
- 2016-11-18
- Accepted Time:
- 2016-11-18 17:12:19
- Original Submission Date:
- 2016-04-21
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1133416 | Galectin Therapeutics Inc | GALT | Pharmaceutical Preparations (2834) | 043562325 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1453356 | 10X Fund, L.p. | 1230 Peachtree Street, N.e., Suite 2445 Atlanta, GA 30309 | No | No | Yes | No | |
1457247 | 10X Capital Management, Llc | 1230 Peachtree Street, N.e., Suite 2445 Atlanta, GA 30309 | No | No | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2016-04-19 | 33,100 | $1.68 | 3,271,909 | No | 4 | S | Direct | |
Common Stock | Disposition | 2016-04-20 | 11,212 | $1.57 | 3,260,697 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct | |
No | 4 | S | Direct |
Footnotes
- Reflects weighted average price. Range of gross prices were between $1.69 and $1.715. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price. This Form 4/A amends the original filing to show the net sales price after deduction of commissions charged by the selling broker.
- Reflects weighted average price. Range of gross prices were between $1.55 and $1.62. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price. This Form 4/A amends the original filing to show the net sales price after deduction of commissions charged by the selling broker.
- 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. 10X Capital Management, LLC disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.